Title : Absence of modulation of CD4+CD25 regulatory T cells in CTCL patients treated with bexarotene.

Pub. Date : 2010 Aug

PMID : 19845755






2 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Bexarotene, the first synthetic highly selective RXR retinoid, was approved for the treatment of all stages of CTCL in patients refractory to at least one systemic therapy. Bexarotene TSPY like 2 Homo sapiens
2 Recently, six cases in which the initiation of bexarotene therapy for CTCL was associated with the progression of internal disease despite improvement of cutaneous signs and symptoms were reported. Bexarotene TSPY like 2 Homo sapiens